Trials / Completed
CompletedNCT02121639
Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy
An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- University Hospital Southampton NHS Foundation Trust · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the ProCAID study is to determine if the addition of the AKT inhibitor AZD5363 to docetaxel and prednisolone (DP) prolongs progression free survival (PFS) in Metastatic castration resistant prostate cancer to a degree worthy of further investigation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | AZD5363 |
Timeline
- Start date
- 2014-01-29
- Primary completion
- 2020-10-08
- Completion
- 2021-09-13
- First posted
- 2014-04-23
- Last updated
- 2022-05-05
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02121639. Inclusion in this directory is not an endorsement.